Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease
- 1 May 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (7) , 761-770
- https://doi.org/10.1097/00002030-200005050-00001
Abstract
It is predicted that HIV-infected individuals in early HIV disease are the most likely group to achieve immune reconstitution following highly active antiretroviral treatment. We assessed whether suppression of HIV replication in this group would improve immune function. Seventeen antiretroviral-naïve patients in early HIV disease were evaluated for immune function and lymphocyte phenotyping using standard immunological assays. Absolute CD4+ T-cell number increased from a median of 550 to 800 × 106 cells/l while CD8+ T-cell numbers were reduced. The decrease in CD8+ cells correlated with a decrease in the CD8+ memory phenotype. Kinetics of CD4+ naïve and memory T-cell rise indicated that 80% of the maximum CD4+ naïve increase was achieved within 18 weeks whereas maximum CD4+ memory T-cell rise was achieved within 36 weeks. Activation markers (HLA-DR, CD38) and an apoptosis-related marker (CD95) were reduced on CD4+ and CD8+ T cells. Lymphocyte proliferation responses to tetanus toxoid, alloantigen, and anti-CD3/CD28 were restored in patients that were initially unresponsive. At baseline, 31% of the patients responded to HIV p24, which increased to 69% post-therapy. The inducible RANTES response was normalized following therapy whereas inducible interferon-γ, interleukin (IL)-12, and MIP1β were elevated. The depressed inducible IL-10 response, however, was not altered after therapy. This is one of the first studies to demonstrate the restoration of HIV-1 specific responses in non-acute HIV infection, suggesting early intervention with potent antiretroviral therapy may reverse immune-mediated damage not seen with treated patients who have more advanced disease.Keywords
This publication has 35 references indexed in Scilit:
- Potent Antiretroviral Therapy of Primary Human Immunodeficiency Virus Type 1 (HIV‐1) Infection: Partial Normalization of T Lymphocyte Subsets and Limited Reduction of HIV‐1 DNA Despite Clearance of Plasma ViremiaThe Journal of Infectious Diseases, 1999
- The human thymus: A new perspective on thymic function, aging, and hiv infectionClinical Immunology Newsletter, 1999
- Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infectionImmunology Letters, 1999
- Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalitiesAIDS, 1998
- Changes in CD4+and CD8+T Cell Subsets in Response to Highly Active Antiretroviral Therapy in HIV Type 1-Infected Patients with Prior Protease Inhibitor ExperienceAIDS Research and Human Retroviruses, 1998
- Antigen–specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytesCurrent Biology, 1998
- Dynamics of fine T-cell subsets during HIV disease and after thymic ablation by mediastinal irradiationSeminars in Immunology, 1997
- CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1α, interleukin‐8 and RANTESEuropean Journal of Immunology, 1995
- The Th1–Th2 hypothesis of HIV infection: new insightsImmunology Today, 1994
- Qualitative Analysis of Immune Function in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1985